Info

Genta Incorporated (Genta) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company focuses on the identification, development and commercialization of drugs for the treatment of cancer and related diseases. Genta’s research portfolio consists of two major programs: DNA/RNA Medicines and Small Molecules. The DNA/RNA Medicines program includes drugs that are based on using modifications of either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) as drugs that can be used to treat disease. This program includes technologies, such as antisense, decoys and small interfering or micro RNAs. Genta’s lead drug from this program is an investigational antisense compound known as Genasense (oblimersen sodium injection). In September 2007, the Company announced that the Food and Drug Administration (FDA) has allowed the investigational new drug (IND) exemption that was submitted by the Company for its new drug known as G4544.(Source: 10-K)